182 related articles for article (PubMed ID: 10779159)
21. Anti-tumor effects of gene therapy with GALV membrane fusion glycoprotein in lung adenocarcinoma.
Zhu B; Yang JR; Fu XP; Jiang YQ
Cell Biochem Biophys; 2014 Jul; 69(3):577-82. PubMed ID: 24519667
[TBL] [Abstract][Full Text] [Related]
22. Gene therapy for acute myeloid leukemia using Sindbis vectors expressing a fusogenic membrane glycoprotein.
Tan L; Xu B; Liu R; Liu H; Tan H; Huang W
Cancer Biol Ther; 2010 Mar; 9(5):350-7. PubMed ID: 20061812
[TBL] [Abstract][Full Text] [Related]
23. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy.
Diaz RM; Bateman A; Emiliusen L; Fielding A; Trono D; Russell SJ; Vile RG
Gene Ther; 2000 Oct; 7(19):1656-63. PubMed ID: 11083474
[TBL] [Abstract][Full Text] [Related]
24. Modification of retroviral tropism by display of IGF-I.
Chadwick MP; Morling FJ; Cosset FL; Russell SJ
J Mol Biol; 1999 Jan; 285(2):485-94. PubMed ID: 9878423
[TBL] [Abstract][Full Text] [Related]
25. Targeting of retroviral vectors through protease-substrate interactions.
Nilson BH; Morling FJ; Cosset FL; Russell SJ
Gene Ther; 1996 Apr; 3(4):280-6. PubMed ID: 8732159
[TBL] [Abstract][Full Text] [Related]
26. Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors.
Lamers CH; Willemsen RA; van Elzakker PM; Gratama JW; Debets R
J Immunother; 2009 Apr; 32(3):272-9. PubMed ID: 19242373
[TBL] [Abstract][Full Text] [Related]
27. Envelope fusion protein binding studies in an inducible model of retrovirus receptor expression and in CD34(+) cells emphasize limited transduction at low receptor levels.
Kurre P; Morris J; Miller AD; Kiem HP
Gene Ther; 2001 Apr; 8(8):593-9. PubMed ID: 11320405
[TBL] [Abstract][Full Text] [Related]
28. Production of Retrovirus-Based Vectors in Mildly Acidic pH Conditions.
Holic N; Fenard D
Methods Mol Biol; 2016; 1448():41-8. PubMed ID: 27317171
[TBL] [Abstract][Full Text] [Related]
29. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
[TBL] [Abstract][Full Text] [Related]
30. Gene therapy of lung adenocarcinoma using herpes virus expressing a fusogenic membrane glycoprotein.
Zhu B; Yang JR; Jiang YQ; Chen SF; Fu XP
Cell Biochem Biophys; 2014 Jul; 69(3):583-7. PubMed ID: 24510538
[TBL] [Abstract][Full Text] [Related]
31. Envelope proteins of spleen necrosis virus form infectious human immunodeficiency virus type 1 pseudotype vector particles, but fail to incorporate upon substitution of the cytoplasmic domain with that of Gibbon ape leukemia virus.
Stitz J; Wolfrum N; Buchholz CJ; Cichutek K
J Gen Virol; 2006 Jun; 87(Pt 6):1577-1581. PubMed ID: 16690921
[TBL] [Abstract][Full Text] [Related]
32. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution.
Guedan S; Grases D; Rojas JJ; Gros A; Vilardell F; Vile R; Mercade E; Cascallo M; Alemany R
Gene Ther; 2012 Nov; 19(11):1048-57. PubMed ID: 22113313
[TBL] [Abstract][Full Text] [Related]
33. Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu.
Lucas TM; Lyddon TD; Cannon PM; Johnson MC
J Virol; 2010 Mar; 84(6):2666-74. PubMed ID: 20042505
[TBL] [Abstract][Full Text] [Related]
34. Episodic Diversifying Selection Shaped the Genomes of Gibbon Ape Leukemia Virus and Related Gammaretroviruses.
Alfano N; Kolokotronis SO; Tsangaras K; Roca AL; Xu W; Eiden MV; Greenwood AD
J Virol; 2016 Feb; 90(4):1757-72. PubMed ID: 26637454
[TBL] [Abstract][Full Text] [Related]
35. Safety testing for replication-competent retrovirus associated with gibbon ape leukemia virus-pseudotyped retroviral vectors.
Chen J; Reeves L; Cornetta K
Hum Gene Ther; 2001 Jan; 12(1):61-70. PubMed ID: 11177543
[TBL] [Abstract][Full Text] [Related]
36. Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells.
Fielding AK; Maurice M; Morling FJ; Cosset FL; Russell SJ
Blood; 1998 Mar; 91(5):1802-9. PubMed ID: 9473249
[TBL] [Abstract][Full Text] [Related]
37. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia.
Chen HH; Cawood R; El-Sherbini Y; Purdie L; Bazan-Peregrino M; Seymour LW; Carlisle RC
Mol Ther; 2011 Jan; 19(1):67-75. PubMed ID: 20877345
[TBL] [Abstract][Full Text] [Related]
38. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer.
Lin EH; Salon C; Brambilla E; Lavillette D; Szecsi J; Cosset FL; Coll JL
Cancer Gene Ther; 2010 Apr; 17(4):256-65. PubMed ID: 19893593
[TBL] [Abstract][Full Text] [Related]
39. [The construction of recombinant type I herpes simplex virus carrying GALV.fus gene and its antitumor effect in nude mice].
Zhu M; Yang JR; Jiang YQ; Chen SF; Fu XP; Tian ZD
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):152-6. PubMed ID: 21500543
[TBL] [Abstract][Full Text] [Related]
40. Gene transfer in bovine blastocysts using replication-defective retroviral vectors packaged with Gibbon ape leukemia virus envelopes.
Kim T; Leibfried-Rutledge ML; First NL
Mol Reprod Dev; 1993 Jun; 35(2):105-13. PubMed ID: 8391277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
